Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy

  • Technology appraisal guidance
  • TA323
  • Published: 

History

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

Anaemia (cancer-treatment induced) - erythropoiesis-stimulating agents (epoetin and darbepoetin) (inc rev TA142): equality impact assessment - guidance development

Anaemia (cancer-treatment induced) - erythropoiesis-stimulating agents (epoetin and darbepoetin) (inc rev TA142) [ID541]: final appraisal determination

Anaemia (cancer-treatment induced) - erythropoiesis-stimulating agents (epoetin and darbepoetin) (inc rev TA142): appraisal consultation

Anaemia (cancer-treatment induced) - erythropoiesis-stimulating agents (epoetin and darbepoetin): Assessment Report

Anaemia (cancer-treatment induced) - erythropoiesis-stimulating agents (epoetin and darbepoetin): protocol

Anaemia (cancer-treatment induced) - erythropoiesis-stimulating agents (epoetin and darbepoetin): final scope

Anaemia (cancer-treatment induced) - erythropoiesis-stimulating agents (epoetin and darbepoetin): final matrix

Anaemia (cancer-treatment induced) - erythropoiesis-stimulating agents (epoetin and darbepoetin): response to consultee and commentator comments on the draft scope and provisional matrix (pre-referral)

Anaemia (cancer-treatment induced) - erythropoiesis-stimulating agents (epoetin and darbepoetin): equality impact assessment - scoping

Anaemia (cancer-treatment induced) - erythropoiesis-stimulating agents (epoetin and darbepoetin): draft scope

Anaemia (cancer-treatment induced) - erythropoiesis-stimulating agents (epoetin and darbepoetin): provisional matrix